← Leaderboards
Qingsheng Li
Virginia Commonwealth University
$6,335,723
Attributed
$11,545,833
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,545,833 · 6
By mechanism
R01$11,129,174 · 5
R21$416,659 · 1
Top collaborators
- Yuxing Li5 shared
- Roger Keith Reeves5 shared
- Jiantao Guo4 shared
- Wenhui Hu3 shared
- Ma Luo1 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Wenhui Hu$15,700,523
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusHiv-1InfectionCellsIn VitroDesignIn VivoCd4 Positive T LymphocytesHumanized MouseLeadMediatingPreventTransmission ProcessMacaca MulattaAntigensImmunityRectalMouse ModelAntiretroviral TherapyBlt MiceViralImmuneCd8b1 GeneClinical Application
Grant awards (21)
Lentivirus-like particle specific delivery of Cas12 ribonucleoprotein (RNP) to HIV reservoir cells in vivo for an HIV cure$836,927
R01 · FY2025 · AI
MEPCS (Multi-epitope protease cleavage sites) vaccine for protecting against SIV rectal transmission$657,563
R01 · FY2025 · AI · contact PI
Lentivirus-like particle specific delivery of Cas12 ribonucleoprotein (RNP) to HIV reservoir cells in vivo for an HIV cure$872,806
R01 · FY2024 · AI
MEPCS (Multi-epitope protease cleavage sites) vaccine for protecting against SIV rectal transmission$650,156
R01 · FY2024 · AI · contact PI
Lentivirus-like particle specific delivery of Cas12 ribonucleoprotein (RNP) to HIV reservoir cells in vivo for an HIV cure$915,099
R01 · FY2023 · AI
Next Generation Broadly Neutralizing Antibodies to Clear HIV-1 Reservoir$778,402
R01 · FY2023 · AI
Next Generation Broadly Neutralizing Antibodies to Clear HIV-1 Reservoir$778,402
R01 · FY2022 · AI
Next Generation Broadly Neutralizing Antibodies to Clear HIV-1 Reservoir$778,402
R01 · FY2021 · AI
Next Generation Broadly Neutralizing Antibodies to Clear HIV-1 Reservoir$778,402
R01 · FY2020 · AI
Impact of the gut microbiome on HIV-1 rectal transmission and immunopathogenesis during ART$188,892
R21 · FY2020 · AI · contact PI
Next Generation Broadly Neutralizing Antibodies to Clear HIV-1 Reservoir$805,652
R01 · FY2019 · AI
Impact of the gut microbiome on HIV-1 rectal transmission and immunopathogenesis during ART$227,767
R21 · FY2019 · AI · contact PI
Improve the safety of an efficacious live-attenuated HIV-1 vaccine through unnatu$484,455
R01 · FY2017 · AI
Improve the safety of an efficacious live-attenuated HIV-1 vaccine through unnatu$484,455
R01 · FY2016 · AI
Improve the safety of an efficacious live-attenuated HIV-1 vaccine through unnatu$464,877
R01 · FY2015 · AI
Improve the safety of an efficacious live-attenuated HIV-1 vaccine through unnatu$485,765
R01 · FY2014 · AI
The Early Events Determining SIV Rectal Transmission$287,675
R01 · FY2013 · DK · contact PI
The Early Events Determining SIV Rectal Transmission$295,479
R01 · FY2012 · DK · contact PI
The Early Events Determining SIV Rectal Transmission$298,303
R01 · FY2011 · DK · contact PI
The Early Events Determining SIV Rectal Transmission$104,924
R01 · FY2011 · DK · contact PI
The Early Events Determining SIV Rectal Transmission$371,430
R01 · FY2010 · DK · contact PI